A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2011-02

AUTHORS

Gabriel N. Waterman, Ori Yellin, Regina A. Swift, Russell Mapes, Benjamin Eades, Emily Ackerman, James R. Berenson

ABSTRACT

Preclinical and clinical studies have demonstrated synergy between bortezomib and pegylated liposomal doxorubicin (PLD) for relapsed/refractory (R/R) multiple myeloma (MM) patients compared to bortezomib as a single agent. This retrospective study evaluated the efficacy and safety of a more frequent low-dose schedule of PLD, bortezomib, and intravenous dexamethasone (DVD) for patients with R/R MM, many of whom were previously treated with bortezomib. Twenty-eight patients with R/R MM were treated, and 23 (83%) had been previously treated with ≥ 1 bortezomib-containing regimen. Treatment consisted of dexamethasone 40 mg intravenously, bortezomib 1.0 mg/m(2), and PLD 5.0 mg/m(2) on days 1, 4, 8, and 11 of a 28-day cycle for a maximum of eight cycles. Patients ranged from 33 to 81 years of age (median, 67) and had received 1-14 prior therapies (median, 5). At baseline, ten, nine, and nine patients were in stages I, II, and III, respectively, as defined by the International Staging System, and eight (29%) patients had elevated serum creatinine levels. The overall response rate was 61%, which included one (4%) complete response, three (11%) very good partial responses, eight (29%) partial responses, and five (18%) minimal responses. Of the 23 patients who had previously received bortezomib, 12 (52%) responded. The regimen was well tolerated with only six patients (21%) who showed worsening of their baseline peripheral neuropathy (PN). One patient discontinued this regimen due to an adverse event (grade II PN). DVD appears to represent a well-tolerated regimen with a high response rate for the treatment of R/R MM patients. More... »

PAGES

193-200

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00277-010-1052-8

DOI

http://dx.doi.org/10.1007/s00277-010-1052-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1010224672

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20809423


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Boronic Acids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bortezomib", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dexamethasone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multiple Myeloma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Polyethylene Glycols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "name": [
            "James R. Berenson, M.D., Inc, West Hollywood, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Waterman", 
        "givenName": "Gabriel N.", 
        "id": "sg:person.01352623505.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352623505.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Oncotherapeutics (United States)", 
          "id": "https://www.grid.ac/institutes/grid.477672.7", 
          "name": [
            "Oncotherapeutics, West Hollywood, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yellin", 
        "givenName": "Ori", 
        "id": "sg:person.0766341055.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0766341055.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "James R. Berenson, M.D., Inc, West Hollywood, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Swift", 
        "givenName": "Regina A.", 
        "id": "sg:person.01046257674.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046257674.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "James R. Berenson, M.D., Inc, West Hollywood, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mapes", 
        "givenName": "Russell", 
        "id": "sg:person.0647045370.10", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647045370.10"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "James R. Berenson, M.D., Inc, West Hollywood, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eades", 
        "givenName": "Benjamin", 
        "id": "sg:person.01255474754.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255474754.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "James R. Berenson, M.D., Inc, West Hollywood, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ackerman", 
        "givenName": "Emily", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute for Myeloma & Bone Cancer Research", 
          "id": "https://www.grid.ac/institutes/grid.418721.9", 
          "name": [
            "James R. Berenson, M.D., Inc, West Hollywood, CA, USA", 
            "Oncotherapeutics, West Hollywood, CA, USA", 
            "Institute for Myeloma and Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, 90069, West Hollywood, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Berenson", 
        "givenName": "James R.", 
        "id": "sg:person.0722327074.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722327074.67"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2005.05519.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004183784"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.2005.05519.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004183784"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.10.5460", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013086836"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.03.2383", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013454488"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.19.5370", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019649645"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020699419"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2004-12-4941", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021046081"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.20006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022825825"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21662", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025410708"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.21662", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025410708"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm199402173300709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026927899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/mcb.21.23.8213-8224.2001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029651579"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2404284", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033553106", 
          "https://doi.org/10.1038/sj.leu.2404284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.leu.2404284", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033553106", 
          "https://doi.org/10.1038/sj.leu.2404284"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm198405243102104", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033834750"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/leu.2009.26", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040865864", 
          "https://doi.org/10.1038/leu.2009.26"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.04.7779", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042177697"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdn018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043077767"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0801479", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043382081"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-1812", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045150937"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/mol.104.003400", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048502956"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2002-06-1768", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049049948"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajh.21517", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050176167"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/ajh.21517", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050176167"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1046/j.1365-2141.1998.00930.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051933965"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.01.133", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064202909"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3892/ijo.28.6.1409", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1071516044"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075250661", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077379990", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077807852", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-02", 
    "datePublishedReg": "2011-02-01", 
    "description": "Preclinical and clinical studies have demonstrated synergy between bortezomib and pegylated liposomal doxorubicin (PLD) for relapsed/refractory (R/R) multiple myeloma (MM) patients compared to bortezomib as a single agent. This retrospective study evaluated the efficacy and safety of a more frequent low-dose schedule of PLD, bortezomib, and intravenous dexamethasone (DVD) for patients with R/R MM, many of whom were previously treated with bortezomib. Twenty-eight patients with R/R MM were treated, and 23 (83%) had been previously treated with \u2265 1 bortezomib-containing regimen. Treatment consisted of dexamethasone 40 mg intravenously, bortezomib 1.0 mg/m(2), and PLD 5.0 mg/m(2) on days 1, 4, 8, and 11 of a 28-day cycle for a maximum of eight cycles. Patients ranged from 33 to 81 years of age (median, 67) and had received 1-14 prior therapies (median, 5). At baseline, ten, nine, and nine patients were in stages I, II, and III, respectively, as defined by the International Staging System, and eight (29%) patients had elevated serum creatinine levels. The overall response rate was 61%, which included one (4%) complete response, three (11%) very good partial responses, eight (29%) partial responses, and five (18%) minimal responses. Of the 23 patients who had previously received bortezomib, 12 (52%) responded. The regimen was well tolerated with only six patients (21%) who showed worsening of their baseline peripheral neuropathy (PN). One patient discontinued this regimen due to an adverse event (grade II PN). DVD appears to represent a well-tolerated regimen with a high response rate for the treatment of R/R MM patients.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00277-010-1052-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1018247", 
        "issn": [
          "1269-3286", 
          "1279-8509"
        ], 
        "name": "Annals of Hematology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "90"
      }
    ], 
    "name": "A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma", 
    "pagination": "193-200", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "30b62a4ff5471076eb712edff1241fa258a15410fc03dfbec94a6ebb9d753e49"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20809423"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9107334"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00277-010-1052-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1010224672"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00277-010-1052-8", 
      "https://app.dimensions.ai/details/publication/pub.1010224672"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T00:08", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8695_00000480.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s00277-010-1052-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00277-010-1052-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00277-010-1052-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00277-010-1052-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00277-010-1052-8'


 

This table displays all metadata directly associated to this object as RDF triples.

286 TRIPLES      21 PREDICATES      76 URIs      42 LITERALS      30 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00277-010-1052-8 schema:about N23e6baabe09541b8946c6601a2207dae
2 N2f561c8f4db846efbce9c4e56edcf55d
3 N308993d22fc54b799c34089d53b1889e
4 N3f4d35316cf142dd985f222471208d70
5 N416d1f59072d4435b2d7d52a5f97d206
6 N46db06d2e60d481c876e73df02ca2d93
7 N49234be6c6574873803a10f91e432359
8 N600a12641c0849f68f105cd7f83fcf28
9 N607bb0d5370a4239aa0edcd788ea6d13
10 N720362ab7b1240df964fa7d02bc9f130
11 N81b0ea4597b04ee4b3db4b53b5991cdf
12 N90b6f65aa8ab4a2e8da78605f72a4689
13 N94bb1980caee4e709ccce55ffe9c2896
14 N9bf048f4678a4ac0b6def17b94ea2d91
15 Naf1377d7d8fd4f6389de51780264b55c
16 Nb1ed51dad86e4e96a2220cafd2674058
17 Nb9e159a35d0940d8ba5ffc4febcbd215
18 Nbf6f32a6b6984cce8272c07c3b498587
19 Nd90f435a4a3b476dab888b0d80277537
20 Ndd0e21b86fef46dbacda0bff6f9b0ec2
21 Nff0dbdcf54e3475b86aee732ad38bf38
22 anzsrc-for:11
23 anzsrc-for:1112
24 schema:author N10782942411a46f499ce1c8de443500a
25 schema:citation sg:pub.10.1038/leu.2009.26
26 sg:pub.10.1038/sj.leu.2404284
27 https://app.dimensions.ai/details/publication/pub.1075250661
28 https://app.dimensions.ai/details/publication/pub.1077379990
29 https://app.dimensions.ai/details/publication/pub.1077807852
30 https://doi.org/10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u
31 https://doi.org/10.1002/ajh.21517
32 https://doi.org/10.1002/cncr.21662
33 https://doi.org/10.1046/j.1365-2141.1998.00930.x
34 https://doi.org/10.1056/nejm198405243102104
35 https://doi.org/10.1056/nejm199402173300709
36 https://doi.org/10.1056/nejmoa0801479
37 https://doi.org/10.1093/annonc/mdn018
38 https://doi.org/10.1111/j.1365-2141.2005.05519.x
39 https://doi.org/10.1124/mol.104.003400
40 https://doi.org/10.1128/mcb.21.23.8213-8224.2001
41 https://doi.org/10.1158/1078-0432.ccr-06-1812
42 https://doi.org/10.1182/blood-2002-06-1768
43 https://doi.org/10.1182/blood-2004-12-4941
44 https://doi.org/10.1200/jco.2002.01.133
45 https://doi.org/10.1200/jco.2005.03.2383
46 https://doi.org/10.1200/jco.2005.04.7779
47 https://doi.org/10.1200/jco.2006.10.5460
48 https://doi.org/10.1200/jco.2008.19.5370
49 https://doi.org/10.3322/caac.20006
50 https://doi.org/10.3892/ijo.28.6.1409
51 schema:datePublished 2011-02
52 schema:datePublishedReg 2011-02-01
53 schema:description Preclinical and clinical studies have demonstrated synergy between bortezomib and pegylated liposomal doxorubicin (PLD) for relapsed/refractory (R/R) multiple myeloma (MM) patients compared to bortezomib as a single agent. This retrospective study evaluated the efficacy and safety of a more frequent low-dose schedule of PLD, bortezomib, and intravenous dexamethasone (DVD) for patients with R/R MM, many of whom were previously treated with bortezomib. Twenty-eight patients with R/R MM were treated, and 23 (83%) had been previously treated with ≥ 1 bortezomib-containing regimen. Treatment consisted of dexamethasone 40 mg intravenously, bortezomib 1.0 mg/m(2), and PLD 5.0 mg/m(2) on days 1, 4, 8, and 11 of a 28-day cycle for a maximum of eight cycles. Patients ranged from 33 to 81 years of age (median, 67) and had received 1-14 prior therapies (median, 5). At baseline, ten, nine, and nine patients were in stages I, II, and III, respectively, as defined by the International Staging System, and eight (29%) patients had elevated serum creatinine levels. The overall response rate was 61%, which included one (4%) complete response, three (11%) very good partial responses, eight (29%) partial responses, and five (18%) minimal responses. Of the 23 patients who had previously received bortezomib, 12 (52%) responded. The regimen was well tolerated with only six patients (21%) who showed worsening of their baseline peripheral neuropathy (PN). One patient discontinued this regimen due to an adverse event (grade II PN). DVD appears to represent a well-tolerated regimen with a high response rate for the treatment of R/R MM patients.
54 schema:genre research_article
55 schema:inLanguage en
56 schema:isAccessibleForFree false
57 schema:isPartOf N192eac670f9845bb918abe08b998bda0
58 N51b1dfb6c3ac4bd7ae586fda8f08ac54
59 sg:journal.1018247
60 schema:name A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma
61 schema:pagination 193-200
62 schema:productId N11b1dbf078564d12a17a835e4e307175
63 N1c9222fa526a4ea2a29549cf088440a4
64 N446db54bb4bb4cc88c7286151cedcd5c
65 N4c58678fb8c54efdaf627badb969f66e
66 Nac4aeee437274d1a93494a2434e7ab6d
67 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010224672
68 https://doi.org/10.1007/s00277-010-1052-8
69 schema:sdDatePublished 2019-04-11T00:08
70 schema:sdLicense https://scigraph.springernature.com/explorer/license/
71 schema:sdPublisher N1c7d168becce40529348e4b19fb9c340
72 schema:url http://link.springer.com/10.1007/s00277-010-1052-8
73 sgo:license sg:explorer/license/
74 sgo:sdDataset articles
75 rdf:type schema:ScholarlyArticle
76 N0ca45d98a99f44fa952af0ef3be6d2e6 rdf:first sg:person.0647045370.10
77 rdf:rest N9f3a9e64ba8746f18f50b83b88829494
78 N10782942411a46f499ce1c8de443500a rdf:first sg:person.01352623505.09
79 rdf:rest Nce165f983d514ca99a9c326053d6ab78
80 N11b1dbf078564d12a17a835e4e307175 schema:name nlm_unique_id
81 schema:value 9107334
82 rdf:type schema:PropertyValue
83 N192eac670f9845bb918abe08b998bda0 schema:issueNumber 2
84 rdf:type schema:PublicationIssue
85 N1c7d168becce40529348e4b19fb9c340 schema:name Springer Nature - SN SciGraph project
86 rdf:type schema:Organization
87 N1c9222fa526a4ea2a29549cf088440a4 schema:name dimensions_id
88 schema:value pub.1010224672
89 rdf:type schema:PropertyValue
90 N23e6baabe09541b8946c6601a2207dae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
91 schema:name Antineoplastic Agents
92 rdf:type schema:DefinedTerm
93 N245d1de0de6f4b21827fdc19587c3920 schema:affiliation Nafe41c1e3aa1402f80fda557b6a0c049
94 schema:familyName Ackerman
95 schema:givenName Emily
96 rdf:type schema:Person
97 N279982e0bb5644098d2a595ad7c1431a rdf:first sg:person.01046257674.12
98 rdf:rest N0ca45d98a99f44fa952af0ef3be6d2e6
99 N2f561c8f4db846efbce9c4e56edcf55d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Recurrence
101 rdf:type schema:DefinedTerm
102 N308993d22fc54b799c34089d53b1889e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Retrospective Studies
104 rdf:type schema:DefinedTerm
105 N3f4d35316cf142dd985f222471208d70 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Male
107 rdf:type schema:DefinedTerm
108 N416d1f59072d4435b2d7d52a5f97d206 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Humans
110 rdf:type schema:DefinedTerm
111 N446db54bb4bb4cc88c7286151cedcd5c schema:name pubmed_id
112 schema:value 20809423
113 rdf:type schema:PropertyValue
114 N46db06d2e60d481c876e73df02ca2d93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Middle Aged
116 rdf:type schema:DefinedTerm
117 N49234be6c6574873803a10f91e432359 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Kaplan-Meier Estimate
119 rdf:type schema:DefinedTerm
120 N4c58678fb8c54efdaf627badb969f66e schema:name doi
121 schema:value 10.1007/s00277-010-1052-8
122 rdf:type schema:PropertyValue
123 N51b1dfb6c3ac4bd7ae586fda8f08ac54 schema:volumeNumber 90
124 rdf:type schema:PublicationVolume
125 N600a12641c0849f68f105cd7f83fcf28 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Aged
127 rdf:type schema:DefinedTerm
128 N607bb0d5370a4239aa0edcd788ea6d13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Disease-Free Survival
130 rdf:type schema:DefinedTerm
131 N720362ab7b1240df964fa7d02bc9f130 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Polyethylene Glycols
133 rdf:type schema:DefinedTerm
134 N77e8468914a14606ae47567f2bf47a66 rdf:first sg:person.0722327074.67
135 rdf:rest rdf:nil
136 N7859ecb77ec3453fb33863fb47863366 rdf:first N245d1de0de6f4b21827fdc19587c3920
137 rdf:rest N77e8468914a14606ae47567f2bf47a66
138 N786bc1dc8d35413cb4cff8551973d90d schema:name James R. Berenson, M.D., Inc, West Hollywood, CA, USA
139 rdf:type schema:Organization
140 N81b0ea4597b04ee4b3db4b53b5991cdf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Pyrazines
142 rdf:type schema:DefinedTerm
143 N90b6f65aa8ab4a2e8da78605f72a4689 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Aged, 80 and over
145 rdf:type schema:DefinedTerm
146 N94bb1980caee4e709ccce55ffe9c2896 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Doxorubicin
148 rdf:type schema:DefinedTerm
149 N9bf048f4678a4ac0b6def17b94ea2d91 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Adult
151 rdf:type schema:DefinedTerm
152 N9f3a9e64ba8746f18f50b83b88829494 rdf:first sg:person.01255474754.43
153 rdf:rest N7859ecb77ec3453fb33863fb47863366
154 Na8e4252c1d7a40fcaa7a3e595cfe6234 schema:name James R. Berenson, M.D., Inc, West Hollywood, CA, USA
155 rdf:type schema:Organization
156 Nac4aeee437274d1a93494a2434e7ab6d schema:name readcube_id
157 schema:value 30b62a4ff5471076eb712edff1241fa258a15410fc03dfbec94a6ebb9d753e49
158 rdf:type schema:PropertyValue
159 Naf1377d7d8fd4f6389de51780264b55c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Female
161 rdf:type schema:DefinedTerm
162 Nafe41c1e3aa1402f80fda557b6a0c049 schema:name James R. Berenson, M.D., Inc, West Hollywood, CA, USA
163 rdf:type schema:Organization
164 Nb1ed51dad86e4e96a2220cafd2674058 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Antineoplastic Combined Chemotherapy Protocols
166 rdf:type schema:DefinedTerm
167 Nb7fc7fcf3958470f88dd77e1c79db011 schema:name James R. Berenson, M.D., Inc, West Hollywood, CA, USA
168 rdf:type schema:Organization
169 Nb9e159a35d0940d8ba5ffc4febcbd215 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Multiple Myeloma
171 rdf:type schema:DefinedTerm
172 Nbf6f32a6b6984cce8272c07c3b498587 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Boronic Acids
174 rdf:type schema:DefinedTerm
175 Ncca510da0a384c9295df3d703d36f21c schema:name James R. Berenson, M.D., Inc, West Hollywood, CA, USA
176 rdf:type schema:Organization
177 Nce165f983d514ca99a9c326053d6ab78 rdf:first sg:person.0766341055.55
178 rdf:rest N279982e0bb5644098d2a595ad7c1431a
179 Nd90f435a4a3b476dab888b0d80277537 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Dexamethasone
181 rdf:type schema:DefinedTerm
182 Ndd0e21b86fef46dbacda0bff6f9b0ec2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Bortezomib
184 rdf:type schema:DefinedTerm
185 Nff0dbdcf54e3475b86aee732ad38bf38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Treatment Outcome
187 rdf:type schema:DefinedTerm
188 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
189 schema:name Medical and Health Sciences
190 rdf:type schema:DefinedTerm
191 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
192 schema:name Oncology and Carcinogenesis
193 rdf:type schema:DefinedTerm
194 sg:journal.1018247 schema:issn 1269-3286
195 1279-8509
196 schema:name Annals of Hematology
197 rdf:type schema:Periodical
198 sg:person.01046257674.12 schema:affiliation Na8e4252c1d7a40fcaa7a3e595cfe6234
199 schema:familyName Swift
200 schema:givenName Regina A.
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046257674.12
202 rdf:type schema:Person
203 sg:person.01255474754.43 schema:affiliation Nb7fc7fcf3958470f88dd77e1c79db011
204 schema:familyName Eades
205 schema:givenName Benjamin
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255474754.43
207 rdf:type schema:Person
208 sg:person.01352623505.09 schema:affiliation Ncca510da0a384c9295df3d703d36f21c
209 schema:familyName Waterman
210 schema:givenName Gabriel N.
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352623505.09
212 rdf:type schema:Person
213 sg:person.0647045370.10 schema:affiliation N786bc1dc8d35413cb4cff8551973d90d
214 schema:familyName Mapes
215 schema:givenName Russell
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647045370.10
217 rdf:type schema:Person
218 sg:person.0722327074.67 schema:affiliation https://www.grid.ac/institutes/grid.418721.9
219 schema:familyName Berenson
220 schema:givenName James R.
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0722327074.67
222 rdf:type schema:Person
223 sg:person.0766341055.55 schema:affiliation https://www.grid.ac/institutes/grid.477672.7
224 schema:familyName Yellin
225 schema:givenName Ori
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0766341055.55
227 rdf:type schema:Person
228 sg:pub.10.1038/leu.2009.26 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040865864
229 https://doi.org/10.1038/leu.2009.26
230 rdf:type schema:CreativeWork
231 sg:pub.10.1038/sj.leu.2404284 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033553106
232 https://doi.org/10.1038/sj.leu.2404284
233 rdf:type schema:CreativeWork
234 https://app.dimensions.ai/details/publication/pub.1075250661 schema:CreativeWork
235 https://app.dimensions.ai/details/publication/pub.1077379990 schema:CreativeWork
236 https://app.dimensions.ai/details/publication/pub.1077807852 schema:CreativeWork
237 https://doi.org/10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u schema:sameAs https://app.dimensions.ai/details/publication/pub.1020699419
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1002/ajh.21517 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050176167
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1002/cncr.21662 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025410708
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1046/j.1365-2141.1998.00930.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1051933965
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1056/nejm198405243102104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033834750
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1056/nejm199402173300709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026927899
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1056/nejmoa0801479 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043382081
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1093/annonc/mdn018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043077767
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1111/j.1365-2141.2005.05519.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1004183784
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1124/mol.104.003400 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048502956
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1128/mcb.21.23.8213-8224.2001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029651579
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1158/1078-0432.ccr-06-1812 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045150937
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1182/blood-2002-06-1768 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049049948
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1182/blood-2004-12-4941 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021046081
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1200/jco.2002.01.133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064202909
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1200/jco.2005.03.2383 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013454488
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1200/jco.2005.04.7779 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042177697
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1200/jco.2006.10.5460 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013086836
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1200/jco.2008.19.5370 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019649645
274 rdf:type schema:CreativeWork
275 https://doi.org/10.3322/caac.20006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022825825
276 rdf:type schema:CreativeWork
277 https://doi.org/10.3892/ijo.28.6.1409 schema:sameAs https://app.dimensions.ai/details/publication/pub.1071516044
278 rdf:type schema:CreativeWork
279 https://www.grid.ac/institutes/grid.418721.9 schema:alternateName Institute for Myeloma & Bone Cancer Research
280 schema:name Institute for Myeloma and Bone Cancer Research, 9201 W. Sunset Blvd., Suite 300, 90069, West Hollywood, CA, USA
281 James R. Berenson, M.D., Inc, West Hollywood, CA, USA
282 Oncotherapeutics, West Hollywood, CA, USA
283 rdf:type schema:Organization
284 https://www.grid.ac/institutes/grid.477672.7 schema:alternateName Oncotherapeutics (United States)
285 schema:name Oncotherapeutics, West Hollywood, CA, USA
286 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...